Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2021 · 10-Q
Revenue$133.52M$133.52M+15.2% vs Q2 2020 Net Income-$14.64M-$14.64MN/M vs Q2 2020 EPS Diluted-$0.14-$0.14N/M vs Q2 2020 Gross Profit$104,918,000+16.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$26,172,000+105.4% Free Cash Flowderived$23,554,000+149.9% Margins · derivedGross margin78.6%+0.6 pt vs Q2 2020
Operating margin-9.2%−15.0 pt vs Q2 2020
Net margin-11.0%−12.4 pt vs Q2 2020
ended Jun 30, 2021 · filed Jul 29, 2021 · 29 d after period end